Table 6. Incremental Cost-Effectiveness Ratios ($/QALY) by Cohort Starting Age, Genotype 1 under Standard Treatment, Base Case Fibrosis Stage Distribution.
Men, Age | 40 | 50 | 60 | 70 |
Do Nothing | – | – | – | – |
FibroTest Only | ED | ED | ED | ED |
FibroTest and Biopsy | D | D | D | D |
FibroTest Rule In | D | D | D | ED |
FibroTest Rule Out | D | D | D | D |
Liver Biopsy Only | D | D | D | D |
Immediate Treatment | $12,100/QALY | $14,800/QALY | $19,900/QALY | $31,600/QALY |
(D: dominated, ED: Extended-Dominated by a combination of Do Nothing and Immediate Treatment).